Obes betegek lipidprofiljának és paraoxonáz aktivitásának változása orlistat kezelést követóen.

M. Audikovszky, G. Pados, I. Seres, M. Harangi, P. Fülöp, E. Katona, G. Winkler, G. Paragh

Research output: Article

3 Citations (Scopus)

Abstract

257 patients from 33 centres were involved in a six-month study, the aim of which was to assess the effect of orlistat together with a diet. The authors examined how the treatment effected the anthropometrical and lipid parameters, extending the study to the aspect of paraoxonase activity in case of 25 patients. 44 patients dropped out during the study period due to the lack of sufficient diet compliance, whereas 3 patients had to stop the therapy because of the adverse event of flatus with discharge. On the average, the body mass of the patients decreased from 100.8 +/- 18.9 to 91.3 +/- 18.6 kg, i.e. by 9.5 kgs, while their BMI was reduced from 36.1 +/- 5.6 to 32.5 +/- 5.2 kg/m2 and the circumference of the waist changing from 119.1 +/- 20 to 108.3 +/- 15.1 cm, i.e. by 10.8 cms. The blood sugar level significantly decreased from 5.7 to 5.4, while the cholesterol concentration significantly dropped from 5.9 to 5.5, the triglyceride level being reduced from 2.4 to 2.1 mmol/l and blood pressure falling significantly from 136.6/86.9 to 129.9/81.6. All the above changes showed a significant decrease. However, the HDL-cholesterol level did not change. The serum paraoxonase activity significantly increased (143 +/- 49 vs 166 +/- 43 UL) along with the standardised values for HDL (PON/HDL), even compared to the control diet group. From the above results it may be concluded that orlistat tends to have an antioxidant effect.

Original languageHungarian
Pages (from-to)2779-2783
Number of pages5
JournalOrvosi Hetilap
Volume142
Issue number50
Publication statusPublished - dec. 16 2001

Fingerprint

Aryldialkylphosphatase
Lipids
Diet
Flatulence
Therapeutics
Waist Circumference
HDL Cholesterol
Compliance
Blood Glucose
Triglycerides
Antioxidants
Cholesterol
orlistat
Blood Pressure
Control Groups
Serum

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Obes betegek lipidprofiljának és paraoxonáz aktivitásának változása orlistat kezelést követóen. / Audikovszky, M.; Pados, G.; Seres, I.; Harangi, M.; Fülöp, P.; Katona, E.; Winkler, G.; Paragh, G.

In: Orvosi Hetilap, Vol. 142, No. 50, 16.12.2001, p. 2779-2783.

Research output: Article

@article{20a6d21adac340deb20339dc72e113b8,
title = "Obes betegek lipidprofilj{\'a}nak {\'e}s paraoxon{\'a}z aktivit{\'a}s{\'a}nak v{\'a}ltoz{\'a}sa orlistat kezel{\'e}st k{\"o}vet{\'o}en.",
abstract = "257 patients from 33 centres were involved in a six-month study, the aim of which was to assess the effect of orlistat together with a diet. The authors examined how the treatment effected the anthropometrical and lipid parameters, extending the study to the aspect of paraoxonase activity in case of 25 patients. 44 patients dropped out during the study period due to the lack of sufficient diet compliance, whereas 3 patients had to stop the therapy because of the adverse event of flatus with discharge. On the average, the body mass of the patients decreased from 100.8 +/- 18.9 to 91.3 +/- 18.6 kg, i.e. by 9.5 kgs, while their BMI was reduced from 36.1 +/- 5.6 to 32.5 +/- 5.2 kg/m2 and the circumference of the waist changing from 119.1 +/- 20 to 108.3 +/- 15.1 cm, i.e. by 10.8 cms. The blood sugar level significantly decreased from 5.7 to 5.4, while the cholesterol concentration significantly dropped from 5.9 to 5.5, the triglyceride level being reduced from 2.4 to 2.1 mmol/l and blood pressure falling significantly from 136.6/86.9 to 129.9/81.6. All the above changes showed a significant decrease. However, the HDL-cholesterol level did not change. The serum paraoxonase activity significantly increased (143 +/- 49 vs 166 +/- 43 UL) along with the standardised values for HDL (PON/HDL), even compared to the control diet group. From the above results it may be concluded that orlistat tends to have an antioxidant effect.",
author = "M. Audikovszky and G. Pados and I. Seres and M. Harangi and P. F{\"u}l{\"o}p and E. Katona and G. Winkler and G. Paragh",
year = "2001",
month = "12",
day = "16",
language = "Hungarian",
volume = "142",
pages = "2779--2783",
journal = "Orvosi Hetilap",
issn = "0030-6002",
publisher = "Akademiai Kiado",
number = "50",

}

TY - JOUR

T1 - Obes betegek lipidprofiljának és paraoxonáz aktivitásának változása orlistat kezelést követóen.

AU - Audikovszky, M.

AU - Pados, G.

AU - Seres, I.

AU - Harangi, M.

AU - Fülöp, P.

AU - Katona, E.

AU - Winkler, G.

AU - Paragh, G.

PY - 2001/12/16

Y1 - 2001/12/16

N2 - 257 patients from 33 centres were involved in a six-month study, the aim of which was to assess the effect of orlistat together with a diet. The authors examined how the treatment effected the anthropometrical and lipid parameters, extending the study to the aspect of paraoxonase activity in case of 25 patients. 44 patients dropped out during the study period due to the lack of sufficient diet compliance, whereas 3 patients had to stop the therapy because of the adverse event of flatus with discharge. On the average, the body mass of the patients decreased from 100.8 +/- 18.9 to 91.3 +/- 18.6 kg, i.e. by 9.5 kgs, while their BMI was reduced from 36.1 +/- 5.6 to 32.5 +/- 5.2 kg/m2 and the circumference of the waist changing from 119.1 +/- 20 to 108.3 +/- 15.1 cm, i.e. by 10.8 cms. The blood sugar level significantly decreased from 5.7 to 5.4, while the cholesterol concentration significantly dropped from 5.9 to 5.5, the triglyceride level being reduced from 2.4 to 2.1 mmol/l and blood pressure falling significantly from 136.6/86.9 to 129.9/81.6. All the above changes showed a significant decrease. However, the HDL-cholesterol level did not change. The serum paraoxonase activity significantly increased (143 +/- 49 vs 166 +/- 43 UL) along with the standardised values for HDL (PON/HDL), even compared to the control diet group. From the above results it may be concluded that orlistat tends to have an antioxidant effect.

AB - 257 patients from 33 centres were involved in a six-month study, the aim of which was to assess the effect of orlistat together with a diet. The authors examined how the treatment effected the anthropometrical and lipid parameters, extending the study to the aspect of paraoxonase activity in case of 25 patients. 44 patients dropped out during the study period due to the lack of sufficient diet compliance, whereas 3 patients had to stop the therapy because of the adverse event of flatus with discharge. On the average, the body mass of the patients decreased from 100.8 +/- 18.9 to 91.3 +/- 18.6 kg, i.e. by 9.5 kgs, while their BMI was reduced from 36.1 +/- 5.6 to 32.5 +/- 5.2 kg/m2 and the circumference of the waist changing from 119.1 +/- 20 to 108.3 +/- 15.1 cm, i.e. by 10.8 cms. The blood sugar level significantly decreased from 5.7 to 5.4, while the cholesterol concentration significantly dropped from 5.9 to 5.5, the triglyceride level being reduced from 2.4 to 2.1 mmol/l and blood pressure falling significantly from 136.6/86.9 to 129.9/81.6. All the above changes showed a significant decrease. However, the HDL-cholesterol level did not change. The serum paraoxonase activity significantly increased (143 +/- 49 vs 166 +/- 43 UL) along with the standardised values for HDL (PON/HDL), even compared to the control diet group. From the above results it may be concluded that orlistat tends to have an antioxidant effect.

UR - http://www.scopus.com/inward/record.url?scp=0035900889&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0035900889&partnerID=8YFLogxK

M3 - Article

C2 - 11820148

AN - SCOPUS:0035900889

VL - 142

SP - 2779

EP - 2783

JO - Orvosi Hetilap

JF - Orvosi Hetilap

SN - 0030-6002

IS - 50

ER -